"Given strong commercial execution in the fourth quarter, we demonstrated substantial growth in our key metrics for LUPKYNIS, including an increased total number of patients on therapy and an uptick in patient start forms in the back half of the fourth quarter, compared to the monthly average in the third quarter of 2022," said Peter Greenleaf, President and CEO of Aurinia. "Given this progress, we believe we have achieved our 2022 full year net product revenue guidance and are positioned to achieve our net revenue guidance from product sales for 2023 in the range of $120-$140 million."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AUPH:
- Biotech Alert: Searches spiking for these stocks today
- Aurinia worth ‘keeping closer eye on’ after settlement, Dealreporter says
- AUPH Blasts Up after Settlement is Reached
- Aurinia price target raised to $11 from $10 at RBC Capital
- Aurinia Pharmaceuticals enters patent settlement pact with Sun Pharmaceutical
